Sign In
Buy NBIX
$175.77
+1.62 (+0.93%)
At Close: Jul 24, 2026
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives Consensus Rating of “Moderate Buy” from Brokerages
03:18am, Friday, 10'th Apr 2026
Neurocrine Biosciences, Inc. (NASDAQ: NBIX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the twenty-two research firms that are presently covering the company, Mark
Soleno withdraws EU rare disease drug application ahead of Neurocrine takeover
01:17pm, Tuesday, 07'th Apr 2026
Soleno Therapeutics said on Tuesday it has voluntarily withdrawn the European marketing application for its rare metabolic disorder drug following acquirer Neurocrine's plans to sharpen focus on
Neurocrine Agrees $2.9 Billion Soleno Deal At 34% Premium
02:28pm, Monday, 06'th Apr 2026
Neurocrine Biosciences (NBIX) is moving to acquire Soleno Therapeutics (SLNO) for $2.9 billion in a deal that could expand its presence in rare genetic disorder
Neurocrine Biosciences, Inc. (NBIX) M&A Call Transcript
11:32am, Monday, 06'th Apr 2026
Neurocrine Biosciences, Inc. (NBIX) M&A Call Transcript
Neurocrine Biosciences to acquire Soleno Therapeutics in $2.9B deal
09:57am, Monday, 06'th Apr 2026
Neurocrine Biosciences (NASDAQ:NBIX) has agreed to acquire Soleno Therapeutics (NASDAQ:SLNO) in an all-cash transaction valued at approximately $2.9 billion, it was announced on Monday. Under the term
Neurocrine to Buy Soleno for $2.9 Billion
07:34am, Monday, 06'th Apr 2026
Neurocrine Biosciences agreed to buy Soleno Therapeutics for $2.9 billion in a move intended to expand its endocrinology and rare-disease portfolio.
Breakfast News: Soleno Soars 30% On Buyout Talk
07:30am, Monday, 06'th Apr 2026
Neurocrine's reported biotech buy, Coinbase's new regulatory approval, and more
This Pharma Stock Is Surging 40%. Neurocrine Is Buying It in $2.9 Billion Deal.
07:24am, Monday, 06'th Apr 2026
Neurocrine Biosciences stock fell after the merger was announced.
Wall Street Breakfast Podcast: PepsiCo Exits Kanye Fest
07:08am, Monday, 06'th Apr 2026
PepsiCo (PEP) drops sponsorship of a major London music festival after controversy over Kanye West as headliner. Anthropic is being courted by the UK for a London expansion and potential dual listing,
Neurocrine to buy Soleno Therapeutics for $2.9 billion
07:07am, Monday, 06'th Apr 2026
Neurocrine Biosciences will acquire rare disease drugmaker Soleno Therapeutics for $2.9 billion in cash, the companies said on Monday.
Neurocrine wants to develop new obesity drugs. It's reportedly nearing an acquisition to accelerate that move.
07:04am, Monday, 06'th Apr 2026
Soleno Therapeutics stock is soaring on Monday in premarket after a report that Neurocrine is nearing a deal to buy the company.
Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio
07:00am, Monday, 06'th Apr 2026
VYKAT™ XR (diazoxide choline) is the First and Only FDA Approved Treatment for Hyperphagia in Prader-Willi Syndrome and Represents a Transformative Therapy Expands Neurocrine's High-Growth Comme
Neurocrine Biosciences to acquire Soleno Therapeutics in $2.9B deal
05:35am, Monday, 06'th Apr 2026
Neurocrine Biosciences (NASDAQ:NBIX) has agreed to acquire Soleno Therapeutics (NASDAQ:SLNO) in an all-cash transaction valued at approximately $2.9...
Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings
08:30am, Thursday, 26'th Mar 2026
Expert panel establishes structured approach to tardive dyskinesia screening, diagnosis and treatment in long-term care, including use of VMAT2 inhibitors New post-hoc KINECT‑PRO™ analysis in adul
Neurocrine Biosciences, Inc. (NBIX) Presents at Stifel 2026 Virtual CNS Forum Transcript
06:22pm, Tuesday, 17'th Mar 2026
Neurocrine Biosciences, Inc. (NBIX) Presents at Stifel 2026 Virtual CNS Forum Transcript
